TrialInternational journal of clinical oncology2020

Phase II multi-institutional prospective trial of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer refractory to fluoropyrimidine with modified dose reduction criteria (CCOG1303).

Daisuke Kobayashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.